NEWS2019-03-20T13:16:52+00:00

Health Europa features news of PD-MitoQUANT

PD-MitoQUANT recently appeared in the news stream of HealthEuropa.eu. Read the story, “The Innovative Medicines Initiative, mitochondrial dysfunction and Parkinson’s". Read the story here. Health Europa highlights the latest trends and developments in health and healthcare from across Europe.  Their platform is a valuable news source to the health sector, allowing them to discuss research and innovation themes, health policy and new technologies. In addition, the website, HealthEuropa.eu has gained Google News approval. It features news, interviews and insightful commentary from leading figures, keeping readers informed and up to date on all aspects of health and care.

April 8th, 2019|

PD-MitoQUANT makes headlines

Here is a list of international and national media coverage of the launch of PD-MitoQUANT: Bioengineer.org: Ireland to lead €7 million Parkinson's research project. Read the story here. SCIENMAG: Ireland to lead €7 million Parkinson's research project. Read the story here. Hospital Pharmacy Europe: Ireland to lead on €7 million Parkinson's research project. Read the story here. Bio Spectrum Asia: Ireland to lead €7 M Parkinson's research project. Read the story here. SiliconRepublic.com: Ireland’s RCSI to lead €7m Parkinson’s research project. Read the story here. Irish Mirror: €7m boost for research into Parkinson's. Read the story here. Noticias de Salud: Ireland to lead €7 million Parkinson's research project. Read the story here. ManufacturingChemist.com: Ireland to lead €7 million Parkinson's research project. Read the story here. Irishhealth.com: Irish team lead major Parkinson's project. Read the story here. BioSpectrum: Ireland to lead €7 million Parkinson's research project. Read the story here. TheInnersane.com: Irish Unit lead preeminent Parkinson’s task. Read the story here. Pharma Business International: New research [...]

March 19th, 2019|

PD-MitoQUANT Official Press release- 12 March 2019

7 million euro awarded for Parkinson’s research through Innovative Medicines Initiative   New, more effective treatments are urgently needed for the more than one million people living with Parkinson’s in Europe today. While there are therapies available for the condition, they do not improve all symptoms, nor do they slow or prevent disease progression over time, and long-term treatment is associated with adverse side effects. PD-MitoQUANT (www.pdmitoquant.eu) is an Innovative Medicines Initiative (IMI - www.imi.europa.eu) research project that will improve our understanding of Parkinson’s so that better treatments can be developed in the future. The project will run for 3 years, starting from 01 February 2019, receiving 4.5 million euro in funding from the EU’s Horizon 2020 programme and 2.46 million euro in-kind from European Federation of Pharmaceutical Industries and Associations (EFPIA) members and Parkinson’s UK. Researchers already know that neurodegenerative diseases, like Parkinson’s, damage cells in our brain. PD-MitoQUANT [...]

March 12th, 2019|

Successful Kickoff Meeting in Dublin

The PD-MitoQUANT team had a very successful kick-off meeting last week in RCSI! We reviewed our work plan and discussed the planned activities for the first year of the project. We're going to be busy! To learn more about the project, check out our Project page. If you're on twitter, join our conversation #pdmitoquant! 08/03/2019, PD MitoQUANT Kick Off Meeting at RCSI, 123 St. Stephen's Green, Dublin 2. (Picture: Lafayette Photography)

March 11th, 2019|

Join the PD-MitoQUANT team in RCSI!

The team at RCSI in Dublin, Ireland are hiring for a post-doctoral position in Parkinson’s research. A two-year full-time Post-Doctoral position is now available in the Centre for Systems Medicine (CSM) and the Department of Physiology and Medical Physics, RCSI (Royal College of Surgeons in Ireland), utilising molecular and cell imaging techniques to investigate the role of mitochondrial dysfunction in Parkinson’s. Check out our Vacancies page for more information!

March 5th, 2019|